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Abstract
Hemophilia is a genetic or acquired disease that leads to spontaneous and 
recurrent bleedings, which affect the joints and muscles, thus determining 
chronic damage to the cartilage which will lead to joint disease and hemophilic 
arthropathy. Even though hemophilic patients were initially thought to have a low 
incidence of atherothrombotic complications, it is now clear that atherothrom-
botic events occur. The administration of plasmatic factor VIII has better clinical 
results in type A hemophilic patients than the transfusion with plasma. We ana-
lyzed five patients with hemophilia type A, aged between 35 and 62 years. Two 
of them had a severe form of hemophilia with factor VIII less than 1%, while the 
other three had a moderate form with factor VIII ranging between 1 and 5%. The 
five patients underwent total knee repair interventions and received substitution 
treatment with clotting factors but also prophylactic anticoagulant treatment. The 
postsurgical evolution of these patients was favorable, with similar hemostatic 
profile as the non-hemophilic patients. Moroctocog alfa is an efficient substitu-
tive treatment that manages to normalize the hemostatic profile of patients. 
Therefore, it is recommended to provide prophylactic antithrombotic therapy 
after the orthopedic interventions.
Keywords: hemophilia, hemophilic arthropathy, orthopedic surgery, hemostasis, 
physiotherapy
1. Introduction
Hemophilia is a disease that has a frequency of approximately 1 in 10,000 
births. It has an X-linked transmission, and it consists in a bleeding disorder due to 
the deficiency of clotting factor VIII (hemophilia A) or factor IX (hemophilia B). 
Hemophilia is a genetic or acquired disease that leads to spontaneous and recurrent 
bleedings, which affect the joints and muscles, thus determining chronic damage to 
the cartilage which will lead to joint disease and hemophilic arthropathy.
There are two major types of hemophilia: type A and type B. These disorders are 
X-linked and consist in hemorrhages, resulting from diminished levels of clotting 
factors VIII and IX. Type A is 5–6 times more frequent than type B. This pathology 
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affects in a symptomatic manner only male patients and is characterized by exces-
sive bleeding, which is installed rather spontaneously or after minimal incidents, 
and is difficult to stop [1].
Hemophilia is a chronic condition that requires a substitution treatment with the 
defective factor. Its severity varies accordingly to the residual factor level. It is clas-
sified as severe (when the clotting factor activity is less than 1%), moderate (1–5%), 
and mild (6–40%).
If not treated hemophilic patients, especially those with very low clotting factor 
activity and severe disease, have recurrent disabling and life-threatening bleed-
ing episodes. Using prophylactic factor therapy may diminish bleeding; therefore 
these novel therapies have changed the prognosis of hemophilic patients, providing 
increased life expectancy and better quality of life [2–4].
Even though hemophilic patients were initially thought to have a low incidence 
of atherothrombotic complications, it is now clear that atherothrombotic events 
occur.
Limited data suggest that hemophilia is not protective against atherosclerosis 
and thrombosis, but this theory is still to be studied in men with severe forms of 
hemophilia without other CVD risk factors, such as active HIV infection [5].
The most common manifestation of hemophilia is represented by bleeding. The 
severity of hemorrhages is correlated with the plasmatic level of clotting factors. 
Therefore, there are patients with mild or minor hemophilia that may not bleed 
excessively until they undergo a surgical intervention or after a trauma.
The accurate diagnostic of hemophilia is mandatory for an optimal manage-
ment. Hemophilia should be suspected in patients with early bruising in childhood, 
with excessive hemorrhages after trauma or surgical intervention, or in patients 
with spontaneous bleeding.
2. Principles of care
Patients with hemophilia need a complex therapeutical management. The most 
important aim is to administrate the deficient clotting factor so that bleedings are 
terminated or prevented. If an acute bleeding occurs, it is important to treat it in the 
first 2 hours.
In order to ease the appropriate management, all patients should carry 
upon them accessible identification information such as diagnosis, severity of 
bleeding disorder, type of treatment product that should be used, and contact 
information.
The patients with hemophilia should benefit from a comprehensive care treat-
ment provided by a team of specialists. This type of care should increase the quality 
of life while reducing morbidity and mortality.
Hemophilic patients should benefit from fitness and physical activity therapy, 
in order to obtain normal neuromuscular development, coordination, healthy body 
weight, and appropriate self-esteem [6].
Adjunctive therapy should be provided consisting in physiotherapy, antifibrino-
lytic drugs, and certain COX-2 inhibitors in order to soothe the pain.
Prophylactic factor replacement therapy should be administrated so that bleed-
ing and joint destruction is prevented, thus preserving a normal musculoskeletal 
function.
Surgery is required for complications related to hemophilia or for unrelated 
disease. The surgical treatment should be done in a comprehensive treatment center 
for hemophilia [7, 8].
3Optimal Management of Elective Joint Replacement Surgery in Patients with Hemophilia
DOI: http://dx.doi.org/10.5772/intechopen.90016
3. Complications of hemophilia
In the majority of cases (90%), the bleeding episodes in hemophilic patients 
occur in the joints, thus leading to hemarthrosis. From all these bleedings, the most 
affected joints are the knees, elbows, and ankles. The affected articulation is usually 
swollen, held in flexion, the mobility being very restricted and painful.
If the deficient clotting factor is given quickly, the hemorrhages can be con-
trolled, and the episode can benefit from conservative orthopedic treatment 
without long-term complications.
If the bleeding persists or if hemorrhages reoccur, the presence of blood in the 
joint may lead to apoptosis of the chondrocytes. When there is too much blood 
present, the synovial membrane will become hypertrophic as it tries to reabsorb the 
blood. From that moment a vicious circle of chronic synovitis develops thus leading 
to join destruction and to hemophilic arthropathy [9, 10] (Figure 1).
The hypertrophic synovial membrane consists of villous formation with 
increased vascularization and chronic inflammatory process. Hemophilic children 
will have hypertrophic epiphyseal growth plates. This bone hypertrophy can 
determine length discrepancies and modifications in contour and angular defor-
mities. Further destruction of the cartilage may appear if the inflammatory and 
hemorrhagic process is not controlled. When the synoviocytes are destroyed, they 
release lysosomal enzymes that promote further cartilage destruction and promote 
chronic inflammation. As the modifications progressively occur and the cartilage of 
the joint degrades, the joint function diminishes, and there are limited and painful 
movements [12–14].
The apparition of hemarthrosis is the most frequent and unfavorable clinical 
expression of a hemorrhage in a hemophilic patient; it has an incidence of 75%. It 
usually appears between 1 and 5 years; if it does occur after 10 years, it is usually 
due to a mitigated condition. The other symptoms that may appear are relapses. 
The trigger is represented by a trauma which is very frequently unnoticeable. The 
most affected joints are in a decreasing order as follows: knees (36%), ankle (30%), 
elbow (23%), hand (6%), shoulder (3%), and hip (2%) [15, 16].
Hemarthrosis usually affects only one joint, but sometimes the bleeding may be 
present in both joints, but the lesions are not symmetric. Relapses usually affect the 
same articulation. Each bleeding episode determines disorders of the joint, thus creat-
ing a predisposition for a relapse. The joint structures will weaken, the muscles become 
atrophic and develop fibrosis thus the join functionality becomes mechanics deficient. 
In order to bleed less, the synovial will become hypertrophic and will have an increased 
vascularization, and this mechanism will lead to a vicious circle. From this moment 
on, a chronic condition begins and is called “hemophilic arthropathy.” This complica-
tion advances slowly during time and induces severe modification of the joint with 
ankylosis. Some experimental studies have proven that a major hemarthrosis induces 
Figure 1. 
Modifications of hemarthrosis in hemophilia [11].
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in the cavity of the joint a dense inflammatory process, while the local tissues change 
their color and become brownish as a result of the hemosiderin deposits that are due to 
the erythrocyte damage. The vessels become hyperplasic, thus creating brittle vessels, 
which are prone to bleeding, therefore inducing a vicious circle: bleeding-vascular 
hyperplasia-bleeding [11, 17, 18].
The surface of the articulation roughens and pannus is formed. The bone located 
in the subchondral region becomes dysmorphic. After 30 days the erosions present 
in the cartilage and bone are obvious.
Different studies have proven that the affected joints are an important factor in 
inducing cartilage destruction in hemophilic patients. Different authors showed 
that the presence of iron in the intra-articular blood induces molecular modifica-
tions that can offer an explanation for the cellular proliferation in the synovial 
membrane (synovitis).
Valentino et al. proved in an experimental study that the bleeding that 
results from a controlled trauma causes joint swelling, synovitis, and hemophilic 
arthropathy.
In order to alleviate these complications, substitutive treatment with deficient 
coagulation factor applied from a young age (primary prophylaxis) represents the 
best therapeutic conduct. Even though primary prophylaxy with the deficient clot-
ting factor is given despite, some patients still have intra-articular hemorrhages, as a 
result of an insufficient dose of coagulation factor or due to a diminished adherence 
to the therapy, while other hemophilic patients may present sub-clinically mani-
fested hemarthroses [19, 20].
If continuous prophylactic therapy with clotting factors is provided, the natural 
course of the arthropathy can be slowed down. One of the most threatening compli-
cations of the therapy with clotting factors is the apparition of alloantibodies that 
are directed against the exogenous molecules of clotting factor. This complication 
appears in one third of the patients, and it increases the likelihood to develop an 
uncontrolled bleeding [20, 21].
4. Emicizumab
There has been a new drug developed for the treatment of hemophilic patients. 
It is called emicizumab, and it is a recombinant antibody that brings activated factor 
IXa and factor X into an adequate conformation that will lead to the activation of 
factor X and therefore will mimic the cofactor function of factor VIIIa. A subcuta-
neous injection with emicizumab that is given once weekly proves to be an efficient 
method to prevent bleeding in the majority of type A hemophilic patients with 
inhibitors to factor VIII. Even more the prevention of bleeding has been observed in 
66% of patients without inhibitors to factor VIII.
5. Moroctocog alfa
The administration of plasmatic factor VIII has better clinical results in type A 
hemophilic patients than the transfusion with plasma. The side effects are linked 
to viral infections transmission such as hepatitis B, C, or HIV; therefore it is bet-
ter to use in clinical practice recombinant clotting factors that are associated with 
a diminished risk of viral transmission. In order to have safer products, there 
have been more modern generations of recombinant factor VIII (rFVIII) devel-
oped, the viral transmission being much lower with each new generation of com-
pounds. The first generation had a human serum albumin in order to stabilize the 
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product. The second-generation compounds have no albumin in their composition, 
but proteins from humans or animals were still allowed in the process of cell cul-
ture. The third-generation compounds have eliminated animal and human proteins, 
but contain murine monoclonal antibodies, which are still used for the purification 
of rFVIII. It was proven that the elimination of the middle portion (domain B) of 
the wild-type FVIII did not diminish the clotting activity. It was also shown that 
the full-length protein had similar effects. These findings helped to discover the 
recombinant FVIII with deletion of the B domain called moroctocog alfa [21, 22].
ReFacto® is a recombinant clotting factor VIII which has a B-domain deletion 
(moroctocog alfa). It has a molecular weight of about 170,000 Da and contains1438 
amino acids.
ReFacto has a similar functionality as endogenous clotting factor VIII. When 
given to a patient with hemophilia, factor VIII will bind to the patient’s intrinsic 
von Willebrand factor. When activated factor VIII becomes a cofactor for activated 
factor IX, thus catalyzing the activation of factor X. The activated factor X will sub-
sequently transform prothrombin in thrombin. The latter will transform fibrinogen 
in fibrin, thus forming the red clot. When giving substitution treatment, the levels 
of factor VIII increase, and the deficiency is temporarily corrected, thus leading to a 
diminishment in bleeding episodes [1, 23].
6. Personal clinical experience
We analyzed five patients with hemophilia type A, aged between 35 and 
62 years. Two of them had a severe form of hemophilia with factor VIII less than 
1%, while the other three had a moderate form with factor VIII ranging between 1 
and 5%. All of them described intense pain as a result of functionally chronic knee 
arthropathies. Thus, the lesions had an indication of endoprosthesis and total knee 
repair. These orthopedic interventions were done by a multidisciplinary team, 
formed by hematologists, orthopedists, and intensive care staff (Figure 2).
Figure 2. 
TKR for severe hemophilic osteoarthritis.
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The orthopedic surgeries were realized after a rigorous hematological control, 
offered through the national protocol for hemophilia. Therefore, all patients 
received the necessary amount of substation therapy with clotting factor. During 
the surgery and in the postprocedural surveillance period, the patients had their 
blood count, hemostasis, and transfusion requirements very thoroughly assessed. 
Also, other postsurgical complications were routinely searched (Figure 3).
The postsurgical evolution of these patients was favorable, with similar hemo-
static profile as the non-hemophilic patients. Only one patient had increased 
bleeding times, as his clotting profile associated also a factor VII deficiency, thus 
requiring blood transfusion.
After the administration of Moroctocog alpha substitution treatment, all five 
patients had a normal clotting profile, thus requiring thromboprophylaxis with 
LMVH (enoxaparin) in order to prevent VTE. An important aspect to be noted 
refers to the fact that the amount of bleeding did not correlate with the levels of 
residual factor. Even more, we noted no differences regarding the volume of blood 
drained after the surgery between patients with moderate or severe hemophilia. 
The elderly patients had similar outcomes with young patients with favorable 
postoperative prognosis, consisting in diminishment of joint pain, improvement in 
Figure 3. 
(A–H) Severe axial deformity. Genu varum in severe hemophilic arthropathy. (A–B) Preoperative X-rays. 
(C–D) Severe genu varum clinically and radiologically. (E–F) Postoperative X-rays. (G–H) Clinical view of 
the knee with axis restored and wound healed.
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functionality, and increased quality of life. We thus concluded that older age is not a 
contraindication for complex surgical intervention.
The systemic substitutive treatment was very efficient and normalized the 
clotting profile of the patients. Therefore, the surgical hemostasis was done without 
using topical agents such as bio surgical gels or foams. Even more the intrasurgi-
cal bleeding of these patients was similar with the hemorrhage seen in patients 
without the diagnosis of hemophilia. The monitorization of the clotting profile of 
the patients was thoroughly done by a hematologist trained in treating hemophilic 
patients requiring elective surgeries. The administration of the substitution therapy 
followed the guidelines described in the National Protocol of Hemophilia. The clot-
ting profile was monitored daily, and the results showed a normal hemostasis after 
the administration of treatment. That is why we decided to give low-molecular-
weight heparin in these patients, as the risk of thromboembolic events increased 
after the normalization of the hemostasis, due to the associated risk factors (age, 
sedentarism, obesity, cardiovascular disease). We chose to give enoxaparin once 
daily in a 1 mg/kg dose, and the clinical and paraclinical results were favorable.
7.  Prophylaxy of thrombosis in hemophilic patients who undergo 
orthopedic surgeries
Pruthi et al. published a paper in 2000 regarding the use of thrombophylaxy 
in patients with hemophilia. They presented the case of a patient with moderate 
hemophilia B, who underwent treatment with factor IX concentrate in order to 
realize a total hip replacement for a hip fracture and developed venous thrombo-
embolism in the operated limb after the intervention. The thrombophilia screening 
detected the presence of a heterozygous type of factor V Leiden mutation [24]. 
Therefore, the authors concluded that presurgical screening for thrombophilia is 
useful in hemophilic patients who had a previous history of VTE. Another research 
realized by Mannucci the same year suggested that all patients with thrombophilia 
should receive short-term therapy with LMWH if they are exposed to significant 
risks such as prolonged immobilization or surgery [25].
Later in 2004, Dargaud et al. suggested that hemophilic patients should not 
routinely receive thromboprophylaxis as there are not enough studies, but they also 
added that hemophilia per se does not protect against venous thromboembolism. 
The conclusion of this study was that specific cases with increased risk of throm-
bosis should receive therapy with LMWH [26]. In 2006 Butcher and Pasi reported 
the case of a patient with hemophilia A, who developed an episode of massive 
pulmonary embolism after major pelvic surgery. Thus, they concluded that throm-
boprophylaxis in selected hemophilic patients is very important [27].
Another research done by Uprichard et al. in 2012 included 13 patients with total 
kidney replacement, from which 11 had hemophilia B. They received mechanical 
thromboprophylaxis, and one also received pharmacological treatment. The results 
were satisfying as no patient suffered VTE [28].
In 2012, Uprichard et al. analyzed a series of 13 TKRs in 11 patients with hemo-
philia B, who received mechanical thromboprophylaxis, and 1 also received phar-
macological thromboprophylaxis. No patients suffered VTE [29].
On the other hand, another study realized by Krekeler et al. in 2012 analyzed 105 
interventions, 90 of them being major orthopedic surgeries and 15 minor surgeries. 
The authors did not find any case of VTE even though therapy with LWMH wasn’t 
given after the surgery. In the same year Ozelo arrived as the same conclusion as 
Butcher and Pasi. Another research from 2013 done by Berntorp stated that in case 
of elderly patients diagnosed with hemophilia or patients with von Willebrand 
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disease, a rigorous assessment of the risk and benefit of thromboprophylaxis in the 
patients who underwent major orthopedic surgery should be realized.
Ozelo et al. proved that the use of graduated compression stockings and early 
mobilization is sufficient in preventing VTE in the majority of patients. Thus, 
the administration of anticlotting therapies should be taken into account just for 
patients that have strong additional risk factors for thrombosis. Contrary, patients 
with hemophilia treated with inhibitors should not receive pharmacological throm-
boprophylaxis. Patients with von Willebrand disease, who receive replacement 
therapy with factor concentrates and who underwent surgical procedures, should 
have a strict monitorization of FVIII plasma levels, and thrombophylaxy should be 
taken into account if there are other thrombotic risk factors [30–32].
8. Conclusions
The best therapy for hemophilic patients consists in doing primary prophylaxy 
so joint bleeding and other complications are prevented. Even though orthopedic 
surgeries in these patients are associated with increased risk of complications such 
as infections and hemorrhages, they can increase significantly the joint mobility 
and life quality if they are realized in specialized centers with hematological sup-
port. Moroctocog alfa is an efficient substitutive treatment that manages to nor-
malize the hemostatic profile of patients. Therefore, it is recommended to provide 
prophylactic antithrombotic therapy after the orthopedic interventions.
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